$OPTN
OptiNose, Inc.

2017 Q4 Form 10-K Financial Statement

#000149465018000025 Filed on March 13, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $18.48M $6.553M $3.588M
YoY Change 920.09% 272.12% 243.02%
% of Gross Profit
Research & Development $1.212M $6.641M $4.749M
YoY Change -60.52% 71.69% 39.19%
% of Gross Profit
Depreciation & Amortization $70.00K $37.00K $34.00K
YoY Change 250.0% 117.65% 70.0%
% of Gross Profit
Operating Expenses $19.70M $13.19M $8.337M
YoY Change 303.44% 134.39% 87.01%
Operating Profit -$19.70M -$13.19M -$8.337M
YoY Change 303.44% 134.39% 87.01%
Interest Expense $110.0K $0.00 $0.00
YoY Change -112.22% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $40.00K $30.00K $40.00K
YoY Change -78.95% -91.89% -50.0%
Pretax Income -$19.55M -$13.07M -$8.210M
YoY Change 249.73% 113.91% 55.79%
Income Tax
% Of Pretax Income
Net Earnings -$19.55M -$13.07M -$8.208M
YoY Change 249.87% 114.02% 55.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.64 -$4.23 -$3.16
Diluted Earnings Per Share -$0.64 -$4.23 -$3.16
COMMON SHARES
Basic Shares Outstanding 37.82M shares 4.068M shares 4.068M shares
Diluted Shares Outstanding 4.068M shares 4.068M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.9M $49.40M $58.90M
YoY Change 538.32%
Cash & Equivalents $234.9M $49.41M $58.93M
Short-Term Investments
Other Short-Term Assets $1.254M $438.0K $1.800M
YoY Change -64.11%
Inventory $2.013M $241.0K
Prepaid Expenses $1.254M
Receivables $0.00 $200.0K $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $238.2M $50.32M $60.90M
YoY Change 485.54%
LONG-TERM ASSETS
Property, Plant & Equipment $2.564M $1.433M $1.100M
YoY Change 693.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $405.0K $1.097M $1.900M
YoY Change -26.76%
Total Long-Term Assets $2.969M $4.815M $3.100M
YoY Change 238.93%
TOTAL ASSETS
Total Short-Term Assets $238.2M $50.32M $60.90M
Total Long-Term Assets $2.969M $4.815M $3.100M
Total Assets $241.1M $55.14M $64.00M
YoY Change 480.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.893M $3.876M $2.300M
YoY Change 74.92%
Accrued Expenses $8.698M $5.606M $3.800M
YoY Change 242.31%
Deferred Revenue $186.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.78M $9.699M $6.200M
YoY Change 150.03%
LONG-TERM LIABILITIES
Long-Term Debt $71.86M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $71.86M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.78M $9.699M $6.200M
Total Long-Term Liabilities $71.86M $0.00 $0.00
Total Liabilities $86.64M $9.699M $6.200M
YoY Change 252.55%
SHAREHOLDERS EQUITY
Retained Earnings -$211.3M -$191.0M
YoY Change 39.82%
Common Stock $365.9M $4.000K
YoY Change 9146800.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $154.5M -$191.1M $57.70M
YoY Change
Total Liabilities & Shareholders Equity $241.1M $55.14M $64.00M
YoY Change 480.34%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$19.55M -$13.07M -$8.208M
YoY Change 249.87% 114.02% 55.9%
Depreciation, Depletion And Amortization $70.00K $37.00K $34.00K
YoY Change 250.0% 117.65% 70.0%
Cash From Operating Activities -$13.81M -$8.240M -$6.100M
YoY Change 132.49% 74.21% 10.31%
INVESTING ACTIVITIES
Capital Expenditures -$1.200M -$500.0K -$620.0K
YoY Change 566.67% 1566.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.200M -$500.0K -$620.0K
YoY Change 566.67% 1566.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.4M -720.0K 1.610M
YoY Change 333933.33%
NET CHANGE
Cash From Operating Activities -13.81M -8.240M -6.100M
Cash From Investing Activities -1.200M -500.0K -620.0K
Cash From Financing Activities 200.4M -720.0K 1.610M
Net Change In Cash 185.4M -9.460M -5.110M
YoY Change -3159.57% 98.74% -7.59%
FREE CASH FLOW
Cash From Operating Activities -$13.81M -$8.240M -$6.100M
Capital Expenditures -$1.200M -$500.0K -$620.0K
Free Cash Flow -$12.61M -$7.740M -$5.480M
YoY Change 118.92% 64.68% -0.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10624486 shares
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001494650
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37865740 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2017Q2 dei Entity Public Float
EntityPublicFloat
0 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
OptiNose, Inc.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016Q4 optn Accrued Interest Noncurrent
AccruedInterestNoncurrent
3409000 USD
CY2017Q4 optn Accrued Interest Noncurrent
AccruedInterestNoncurrent
0 USD
CY2016Q4 optn Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
736000 USD
CY2017Q4 optn Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
80000 USD
CY2016Q4 optn Accrued Selling Generaland Administrative Current
AccruedSellingGeneralandAdministrativeCurrent
290000 USD
CY2017Q4 optn Accrued Selling Generaland Administrative Current
AccruedSellingGeneralandAdministrativeCurrent
3463000 USD
CY2017 optn Debt Discount Amortization Period
DebtDiscountAmortizationPeriod
P5Y6M
CY2015 optn Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses
DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
0 USD
CY2016 optn Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses
DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
0 USD
CY2017 optn Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses
DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses
2454000 USD
CY2016Q4 optn Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
677000 USD
CY2017Q4 optn Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
783000 USD
CY2015 optn Increase Decrease In Grantsand Other Receivables
IncreaseDecreaseInGrantsandOtherReceivables
-144000 USD
CY2016 optn Increase Decrease In Grantsand Other Receivables
IncreaseDecreaseInGrantsandOtherReceivables
-65000 USD
CY2017 optn Increase Decrease In Grantsand Other Receivables
IncreaseDecreaseInGrantsandOtherReceivables
-337000 USD
CY2015 optn Increase Decreasein Depositsand Other Assets
IncreaseDecreaseinDepositsandOtherAssets
-1504000 USD
CY2016 optn Increase Decreasein Depositsand Other Assets
IncreaseDecreaseinDepositsandOtherAssets
3888000 USD
CY2017 optn Increase Decreasein Depositsand Other Assets
IncreaseDecreaseinDepositsandOtherAssets
-2387000 USD
CY2017 optn Interest Expense Debt Back End Fees
InterestExpenseDebtBackEndFees
2000000 USD
CY2017 optn Number Of Operating Leases
NumberOfOperatingLeases
4 lease
CY2017Q4 optn Vote Per Share
VotePerShare
1 vote
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.154
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1390000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3369000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5893000 USD
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4163000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2541000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8698000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
374000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
355000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-99000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-111000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
0 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
365838000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
588000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5096000 USD
CY2015 us-gaap Advertising Expense
AdvertisingExpense
44000 USD
CY2016 us-gaap Advertising Expense
AdvertisingExpense
26000 USD
CY2017 us-gaap Advertising Expense
AdvertisingExpense
1833000 USD
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
588000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
599000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5096000 USD
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
195000 USD
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
776000 USD
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
198000 USD
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27047923 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26009856 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4031856 shares
CY2017Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
20050 sqft
CY2016Q4 us-gaap Assets
Assets
41551000 USD
CY2017Q4 us-gaap Assets
Assets
241136000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
40675000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
238167000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24883000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15198000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36797000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234854000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9685000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21599000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
198057000 USD
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36797000 USD
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
234854000 USD
CY2016Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
35866000 USD
CY2017Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
233772000 USD
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.16
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1890489 shares
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4067717 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37802556 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4067717 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37802556 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
38000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28327000 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22655000 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48914000 USD
CY2015 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2016 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2017 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
237259000 USD
CY2016Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
15256000 USD
CY2017Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 USD
CY2017Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
2140000 USD
CY2015Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
265000 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
46000 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
186000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27186000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35632000 USD
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2183000 USD
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2485000 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22695000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29636000 USD
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
55000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
539000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
972000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1092000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1701000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27140000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35632000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
46000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0 USD
CY2016 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
0 USD
CY2017 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
230000 USD
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1201000 USD
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
0 USD
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
499000 USD
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
329000 USD
CY2015 us-gaap Depreciation
Depreciation
75000 USD
CY2016 us-gaap Depreciation
Depreciation
83000 USD
CY2017 us-gaap Depreciation
Depreciation
164000 USD
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75000 USD
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.52
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
164000 USD
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.97
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.10
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.18
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.87
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.16
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.23
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.63
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.97
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.10
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.87
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.16
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.23
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
73000 USD
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.63
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-14000 USD
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
39000 USD
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.122
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.042
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-11000 USD
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.214
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
125000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
633000 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.167
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.005
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.014
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.008
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-89000 USD
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-60000 USD
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000 USD
CY2017Q4 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
209000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-4967000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30463000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
27580000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-18439000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
22613000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-48902000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
450000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-130000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
392000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3814000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1097000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5834000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-211000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-41000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
186000 USD
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
669000 USD
CY2016 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2740000 USD
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
668000 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2013000 USD
CY2015 us-gaap Interest Expense
InterestExpense
819000 USD
CY2016 us-gaap Interest Expense
InterestExpense
3517000 USD
CY2017 us-gaap Interest Expense
InterestExpense
910000 USD
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
45000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0 USD
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0 USD
CY2016Q4 us-gaap Inventory Gross
InventoryGross
0 USD
CY2017Q4 us-gaap Inventory Gross
InventoryGross
2013000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
2013000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
0 USD
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1385000 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
628000 USD
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000 USD
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
143000 USD
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
303000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
22180000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
7303000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
8337000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
24575000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
86640000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41551000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
241136000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5910000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14777000 USD
CY2015 us-gaap Licenses Revenue
LicensesRevenue
85000 USD
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
47500000 USD
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2016Q3 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2016Q4 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2016 us-gaap Licenses Revenue
LicensesRevenue
47500000 USD
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017Q2 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017Q3 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017Q4 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
71863000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19123000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
236125000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-215000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2406000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28714000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21720000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35651000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-28314000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
39572000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-5265000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-6106000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-5588000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
22613000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-8075000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-8208000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-13068000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-19551000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-48902000 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40375000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
36294000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8544000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9385000 USD
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8866000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
7211000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
4458000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
5629000 USD
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
9499000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11671000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12836000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17192000 USD
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20268000 USD
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61967000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
28162000 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
4882000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
13194000 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
19696000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
48530000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-28077000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
40289000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4458000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5629000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4882000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
25320000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7303000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8337000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13194000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19696000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-48530000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
187000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
187000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
312000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
407000 USD
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
689000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
314000 USD
CY2016Q4 us-gaap Other Assets
OtherAssets
4047000 USD
CY2017Q4 us-gaap Other Assets
OtherAssets
1659000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3494000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1254000 USD
CY2016Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
54000 USD
CY2017Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
76000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
553000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
405000 USD
CY2015 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-13000 USD
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
42000 USD
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-12000 USD
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13000 USD
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
42000 USD
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000 USD
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2038000 USD
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 USD
CY2015 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
162000 USD
CY2016 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2017 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
13433000 USD
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
288000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
215000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2406000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14285000 USD
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
255000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1254000 USD
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
138000000 USD
CY2015 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
75000000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
134000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
697000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2919000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
323000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2564000 USD
CY2017Q4 us-gaap Purchase Obligation
PurchaseObligation
0 USD
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
384000 USD
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
46000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22156000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4961000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3412000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3868000 USD
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3070000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15311000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3073000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5906000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6641000 USD
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1212000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16832000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151102000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211269000 USD
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
643000 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
727000 USD
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
162000 USD
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6006000 USD
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2250000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1046000 USD
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1761000 USD
CY2016Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1812000 USD
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6869000 USD
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4230000 USD
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2431000 USD
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6553000 USD
CY2017Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18484000 USD
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31698000 USD
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
18049 shares
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41283 shares
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
237259000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
588000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
599000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
5096000 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
125471000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-154000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-151197000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
154496000 USD
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-121592000 USD
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-161392000 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-151197000 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
154496000 USD
CY2017Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2.8879
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2069000 USD
CY2016 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2109000 USD
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1096000 USD
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
168173000 USD
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2015 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
9992000 USD
CY2016 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
11005000 USD
CY2017 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
11969000 USD
CY2016Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
6875514 shares
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
8932851 shares
CY2016Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
0.001 USD
CY2017Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8492000 USD
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4049668 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4980181 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10999121 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4049668 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4054316 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10999121 shares
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OptiNose,&#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, Oslo, Norway and Swindon, England. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first two products approved by the United States Food and Drug Administration (FDA) utilize its proprietary Exhalation Delivery Systems (EDS), which are capable of deep intranasal deposition of medication. OptiNose developed its first product, Onzetra</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> Xsail</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> (sumatriptan nasal power) through the completion of Phase III clinical trials and subsequently out-licensed the product to Avanir Pharmaceuticals,&#160;Inc (Avanir). Onzetra Xsail received FDA approval and was launched in the United States (US) in 2016. The Company's second product, XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:Arial;font-size:10pt;"> (fluticasone propionate) nasal spray, 93 mcg, is a therapeutic that utilizes its EDS to deliver a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. On September 18, 2017, the FDA approved the Company's New Drug Application (NDA) for XHANCE for the treatment of nasal polyps in patients 18 years of age or older, and XHANCE is in development for the treatment of chronic sinusitis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2017, the Company completed an initial public offering (IPO) of its common stock, selling </font><font style="font-family:Arial;font-size:10pt;">8,625,000</font><font style="font-family:Arial;font-size:10pt;"> shares at </font><font style="font-family:Arial;font-size:10pt;">$16.00</font><font style="font-family:Arial;font-size:10pt;"> per share. As a result of the IPO, the Company received </font><font style="font-family:Arial;font-size:10pt;">$125,471</font><font style="font-family:Arial;font-size:10pt;"> in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$9,660</font><font style="font-family:Arial;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$2,869</font><font style="font-family:Arial;font-size:10pt;"> payable by the Company. Upon consummation of the IPO, all of the outstanding shares of the Company&#8217;s redeemable convertible preferred stock were converted into an aggregate of </font><font style="font-family:Arial;font-size:10pt;">25,068,556</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</font></div></div>

Files In Submission

Name View Source Status
0001494650-18-000025-index-headers.html Edgar Link pending
0001494650-18-000025-index.html Edgar Link pending
0001494650-18-000025.txt Edgar Link pending
0001494650-18-000025-xbrl.zip Edgar Link pending
auditorconsent10-kex231.htm Edgar Link pending
edsworks.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
formindemnificationagreeme.htm Edgar Link pending
gammamri.jpg Edgar Link pending
gammamri2.jpg Edgar Link pending
liquideds.jpg Edgar Link pending
listofsubsidiariesex211.htm Edgar Link pending
nasalpassage.jpg Edgar Link pending
navigatei.jpg Edgar Link pending
navigateii.jpg Edgar Link pending
optinoselogorgba04.jpg Edgar Link pending
optinose_athyriumxnotepurc.htm Edgar Link pending
optn-20171231.xml Edgar Link completed
optn-20171231.xsd Edgar Link pending
optn-20171231_cal.xml Edgar Link unprocessable
optn-20171231_def.xml Edgar Link unprocessable
optn-20171231_lab.xml Edgar Link unprocessable
optn-20171231_pre.xml Edgar Link unprocessable
optn12-31x201710xk.htm Edgar Link pending
optn12-31x201710xkex311.htm Edgar Link pending
optn12-31x201710xkex312.htm Edgar Link pending
optn12-31x201710xkex321.htm Edgar Link pending
optn12-31x201710xkex322.htm Edgar Link pending
pipeline.jpg Edgar Link pending
powderedsa01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stockperformacegrapha01.jpg Edgar Link pending